Ameriprise Financial »

Inhibikase Therapeutics shares owned by Ameriprise Financial

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Ameriprise Financial from 13F filings

Historical chart of Ameriprise Financial investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Ameriprise Financial consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Ameriprise Financial

Quarter filed Position value Share count Share price at filing
2025-12-31 $2.8M 1.4M 2.05

More positions owned by Ameriprise Financial

NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Alphabet Inc Class A cs (GOOGL)
Broadcom (AVGO)
Amazon (AMZN)
JPMorgan Chase & Co. (JPM)
iShares S&P 500 Index (IVV)
Facebook Inc cl a (META)
Visa (V)
Lam Research (LRCX)
Alphabet Inc Class C cs (GOOG)
Bank of America Corporation (BAC)
Wal-Mart Stores (WMT)
Vanguard S&p 500 Etf idx (VOO)

View all positions for Ameriprise Financial

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
ADAR1 Capital Management
Siren
Perceptive Advisors
Commodore Capital
Vanguard Group
Nantahala Capital Management
Saturn V Capital Management
BlackRock
Blackstone Group
Stonepine Capital Management
Integral Health Asset Management
Ameriprise Financial

View all funds holding Inhibikase Therapeutics